Immutep Ltd · ASX:IMM
Immutep — Emergence Conference 2019
18 slides from Immutep's conference presentation, Feb 25, 2019
Slide 1: Immutep Presentation to Emergence Conference (ASX media release)
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) For personal use only Immutep Presentation to Emergence Conference SYDNEY, AUSTRALIA – 25 February 2019 - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer a
Slide 2: The global leader in developing LAG-3 therapeutics
For personal use only The global leader in developing LAG-3 therapeutics Emergence Conference - Brisbane / Sydney - February 2019 (ASX: IMM, NASDAQ: IMMP)
Slide 3: Notice: Forward Looking Statements
Notice: Forward Looking Statements For personal use only The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further
Slide 4: Company Snapshot
Company Snapshot For personal use only Capital Structure • Globally active biotechnology company with IMM (Australian Securities Exchange) Ticker symbols IMMP (NASDAQ) operations in Australia, Europe and U.S. 3.38 billion ordinary shares Securities on issue(1) 11.2 million American Depository (as at
Slide 5: LAG-3 Overview & Product Candidates
For personal use only LAG-3 Overview & Product Candidates 4
Slide 6: Targeting LAG-3/MHC II May Lead to Multiple Therapeutics in Numerous Indications
Targeting LAG-3/MHC II May Lead to Multiple Therapeutics in Numerous Indications For personal use only IMMUNOSTIMULATION IMMUNOSUPPRESSION IMP321 APC Activator APC Agonistic mAb IMP761 MHCII Depleting LAG-3 mAb Antagonistic Partnered with mAb Partnered with LAG-3 IMP701 T-Cell T-Cell IMP731 Rheumato
Slide 7: Immutep Controlled Immunotherapy Pipeline
Immutep Controlled Immunotherapy Pipeline* For personal use only Program Preclinical Phase I Phase II Late Stage Commercial Rights/Partners Oncology AIPAC (Chemo-IO Combo) Metastatic Breast Cancer 2019 TACTI-002 (1),(4) 2019 § Global (IO-IO Combo) NSCLC (1st/2nd L.) HNSCC (2nd) Rights Eftilagimod Al
Slide 8: Out-Licensed Immunotherapy Pipeline
Out-Licensed Immunotherapy Pipeline For personal use only Program Preclinical Phase I Phase II Late Stage Commercial Rights/Partners Oncology IO-IO Combo: Solid Tumors + Blood Cancer LAG525 Chemo-IO Combo: Triple Negative Breast Cancer (AntagonistAB) Global § Rights IO-IO-Small Molecule Combo: Melan
Slide 9: Lead Program Eftilagimod Alpha (IMP321)
For personal use only Lead Program Eftilagimod Alpha (IMP321) 8
Slide 10: Opportunity for Eftilagimod Alpha
Opportunity for Eftilagimod Alpha For personal use only Eftilagimod has the potential to be an ideal combinatory therapeutic in the oncology treatment regiment that could improve the prognosis for patients Eftilagimod Key Characteristics (based on current data): • First-in-class MHCII agonist • Good
Slide 11: Efti (IMP321) in Melanoma
Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Single Case at 1 mg efti For personal use only Efficacy: Metastatic Melanoma pre-pembro week 9 (pembro) week 25 (combo) week 37 (combo) R L R L R L R L Tumour progression week 49 (Pembro mono) week 64 (PFS-FU) R L R L • Patient progressing on pe
Slide 12: LAG-3 Landscape
11 For personal use only LAG-3 Landscape
Slide 13: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview For personal use only Immutep is the leader in developing LAG-3 modulating therapeutics Program Eftilagimod Alpha (IMP321) LAG525 (IMP701) GSK2831781 (IMP731) Relatlimab Company BMS Late stage 1 trial 1 trial 2 trials Phase 2 1 trial 3trials 11 trials Phase 1 3tr
Slide 14: Increasing Clinical Trials Targeting LAG-3
Increasing Clinical Trials Targeting LAG-3 For personal use only Industry increasingly deploying resources to development of LAG-3 therapeutics 50 14,000 47 45 43 11,610 12,000 Total Estimated Patients in LAG-3 Trials 40 10,906 Number of LAG-3 Clinical Trials 35 10,000 30 8,000 25 21 6,000 20 15 15
Slide 15: Outlook
14 For personal use only Outlook
Slide 16: Outlook: Potential News Flow and Milestones
Outlook For personal use only Potential News Flow and Milestones TACTI-mel data from fourth patient cohort (30 mg dose at cycle 1) in 2019 R&D TACTI-002 to commence, Phase II trial in collaboration with MSD: H1 2019 TACTI-002 first data in 2019 INSIGHT-004 to commence, IIT Phase I trial in collabora
Slide 17: Investment Highlights
Investment Highlights For personal use only The global leader in Broadest LAG-3 portfolio developing LAG-3 Deep expertise and with four product candidates, therapeutics for IP in the LAG-3 immune three of which are in nine immuno-oncology and control mechanism ongoing or planned clinical autoimmune
Slide 18: Thank you!
17 For personal use only Thank you!